NCT06790420 2025-05-31RITUXIMAB BS Intravenous Infusion 100mg・500mg [Pfizer] Post-marketing Database StudyPfizerCompleted1 enrolled
NCT03098589 2025-03-30Revlimid® Capsules Drug Use-results Surveillance (Relapsed or Refractory ATLL)CelgeneCompleted1,149 enrolled
NCT02921828 2022-07-05A Safety and Efficacy of Pomalyst® Capsules Under the Actual Use in All Patients Who Are Treated With Pomalyst at a Dose of 1 mg, 2 mg, 3 mg, or 4 mgCelgeneCompleted1,149 enrolled
NCT02921802 2022-06-14A Study of Special Use Results Surveillance of Revlimid 5mg CapsulesCelgeneCompleted4,626 enrolled
NCT02922543 2022-06-14A Safety and Efficacy Study of Revlimid® 5 mg Capsules in Patients With Relapsed or Refractory Multiple Myeloma Who Have Received Long-term Treatment With it Under the Actual Condition of UseCelgeneCompleted361 enrolled
NCT03087370 2018-12-07A Retrospective and Prospective Natural History Study of Patients With WHIM SyndromeX4 PharmaceuticalsWithdrawn
NCT01062074 2017-04-17GARDASIL Reexamination Study (V501-059)Merck Sharp & Dohme LLCCompleted3,605 enrolled 6 charts